Why is Nectar Lifesci. falling/rising?

As of 14-Jul, Nectar Lifescience Ltd is experiencing a decline in its stock price, currently at 18.94, which reflects a decrease of 0.99 or 4.97%. The stock has underperformed significantly, with a 1-week return of -18.22% compared to the Sensex's -1.42%, and a year-to-date decline of -51.44% against the Sensex's gain of 5.27%. Today's price summary indicates that the stock has fallen after two consecutive days of gains and is trading below all key moving averages. Additionally, the company is facing substantial operational challenges, including a negative EBITDA and a high debt-to-EBITDA ratio, which contribute to its weak long-term fundamental strength. The recent quarterly profit after tax has plummeted by 3160.9%, further exacerbating investor concerns.
In the broader market context, Nectar Lifescience's recent performance starkly contrasts with the benchmark indices, as it has significantly underperformed the BSE500 over various time frames, including the last three years and one year. The stock's liquidity remains adequate, but the high percentage of pledged promoter shares adds to the downward pressure in a falling market. Overall, the combination of poor financial performance, operational losses, and negative investor sentiment has led to the stock's continued decline.